On May 28, 2022 FORUS reported that it was a proud sponsor and participant in the Défi Cyclo-Myélome (Press release, FORUS Therapeutics, MAY 28, 2022, View Source;utm_medium=rss&utm_campaign=forus-was-a-proud-sponsor-and-participant-in-the-defi-cyclo-myelome-on-may-28th-2022 [SID1234615259]). This is the 10th year of this important event which aims to increase awareness about multiple myeloma and raise funds for the Myeloma Canada Chair, held by Dr. Richard LeBlanc, at the Université de Montréal at Maisonneuve-Rosemont Hospital (HMR). Funds from this event will support research focused on improving the care of individuals living with multiple myeloma. Special recognition to Marie-Josèphe Champagne who rode on behalf of FORUS alongside other supporters, patients, caregivers and healthcare professionals.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 27, 2022 KDx Diagnostics and UroGPO reported the partnership to provide the URO17 test (Research Use Only in the US) for the detection of bladder cancer (Press release, KDx Diagnostics, MAY 27, 2022, View Source [SID1234615212]). URO17 is a non-invasive urine test with high sensitivity and negative predicted value (NPV) that can be used to determine the status of active bladder cancer and to improve patient diagnosis. This is also likely to improve the treatment path as URO17 is also now available as a Laboratory Developed Test (LDT) in the United States. UroGPO will offer reagents and information for the URO17 test to the members of their Group Purchasing Organization.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With over 85,000 new cases of bladder cancer in the United States every year the most common symptom of bladder cancer is hematuria, or blood in the urine, and patients with hematuria need to be subjected to invasive cystoscopic procedures even though a large majority of patients with micro-hematuria will not have bladder cancer. The URO17 test, and its high sensitivity and NPV for bladder cancer, will assist in ruling these patients out for unnecessary cystoscopy and its invasive procedure and in turn reduce the work-up.

KDx Diagnostics Inc. and UroGPO Announce a Partnership to Offer the URO17 NON-INVASIVE Urine Test for Bladder Cancer

"We are very excited to partner with UroGPO, the premier urology network and group purchasing organization in the US, to make our URO17 test and information available to their network of clinical laboratories. Through UroGPO, the urology laboratories will have direct access to ordering with a special in-network pricing which will facilitate the availability of URO17 to the urologists," says Sholeh Jahanfard, President of KDx Diagnostics Inc.

"UroGPO is happy to present this new partnership to our membership. The URO17 test adds efficiency and precision to the care of patients with bladder cancer. KDx has taken steps to remove barriers of access for both physicians and patients which will ultimately benefit patient outcomes, improve quality of life, and even mortality," says Palmer DePetro, Sr. Director, Contracting at Specialty Networks.

On May 27, 2022 Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, reported that company management will participate in the following conferences and invited investors to participate by webcast (Press release, Exact Sciences, MAY 27, 2022, View Source [SID1234615178]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

William Blair 42nd Annual Growth Stock Conference, Chicago
Presentation on Monday, June 6, 2022 at 3:40 p.m. ET

Jefferies Healthcare Conference, New York
Fireside Chat on Wednesday, June 8, 2022 at 1:00 p.m. ET

Goldman Sachs 43rd Annual Global Healthcare Conference, Rancho Palos Verdes
Fireside Chat on Monday, June 13, 2022 at 6:20 p.m. ET

Nephron Liquid Biopsy Innovation Symposium, virtual
Fireside Chat on Tuesday, June 21, 2022 at 11:00 a.m. ET
The webcasts can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.com.

On May 27, 2022 Jacobio Pharma (1167.HK) reported that the phase I clinical data of KRAS G12C inhibitor JAB-21822 will be presented in the form of poster at the upcoming 2022 annual meeting of American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) from June 3, 2022 to June 7, 2022 (Press release, Jacobio Pharmaceuticals, MAY 27, 2022, View Source [SID1234615213]). Abstract was published on the ASCO (Free ASCO Whitepaper)’s website today.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"JAB-21822 is one of Jacobio’s programs targeting on KRAS pathway, we plan to explore the JAB-21822 in colorectal cancer, pancreatic cancer, and other indications. Meanwhile, Jacobio is exploring combination therapies of JAB-21822, such as in combination with SHP2 inhibitor. We are also developing novel drugs in KRAS pathway, including KRASmulti inhibitor (JAB-23400) and KRAS G12D inhibitor (JAB-22000)," said Dr. WANG Yinxiang, Chairman and CEO of Jacobio.

About the Abstract

A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.

Format: Poster Presentation

Abstract Number: 3089

Time: Sunday, June 5, 2022 8:00 AM-11:00 AM (CDT)

Track: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology

As of January 28th, 2022, 53 patients with a median age of 62 years (39-79) were enrolled in 5 different dose levels: 200mg QD, 400mg QD, 800mg QD, 400mg BID and 400mg TID. A total of 33 patients (22 non-small cell lung cancer, 9 colorectal cancer and 2 pancreatic cancer) had at least 1 post-baseline tumor assessment.

Patients with non-small cell lung cancer (400mg QD and 800mg QD), the overall response rate (ORR) and disease control rate (DCR) were 70% (7/10) and 100% (10/10), respectively.
No dosing-limiting toxicities were observed.
JAB-21822 was well tolerated with impressive preliminary efficacy in patients with heavily treated solid tumors harboring KRAS G12C mutation. The clinical trial is still ongoing and the above data is as of January 28, 2022.

More data will be posted on the poster at the 2022 ASCO (Free ASCO Whitepaper) Annual Meeting, please visit www.asco.org for more information.

About JAB-21822

JAB-21822 is a KRAS G12C inhibitor independently developed by Jacobio. Jacobio has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients with advanced solid tumors, including monotherapy for STK11 co-mutated non-small cell lung cancer first-line treatment; combination therapy with SHP2 inhibitor, PD-1 monoclonal antibody and Cetuximab.

On May 27, 2022 Herantis Pharma Plc ("Herantis"), developing disease modifying therapies for Parkinson’s disease, reported that interim CEO Frans Wuite will be presenting at the Redeye Growth Day on June 2th, 2022 (Press release, Herantis Pharma, MAY 27, 2022, View Source,c3575325 [SID1234615179]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Redeye Growth Day

The presentation will be live on the Redeye platform at 9:25 a.m. CEST

Follow this link to the event: Redeye Growth Day.

The presentations will be available via digital libraries, which are accessible to event participants only.

Please contact the conference organizers, or send an email to [email protected], if you wish to schedule a meeting with Herantis.